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Abstract 
Chronic treatment of rats with R-PIA 'in vivo' desensitized adenosine A~ receptor-mediated inhibition of adenylyl cyclase in brain 
plasma membranes and increased basal and forskolin-stimulated a enylyl cyclase. The adenosine A I receptor agonist CHA (cyclohexyl 
adenosine) inhibited forskolin-stimulated a enylyl cyclase in synaptic plasma membranes from control rats but failed to do so in 
membranes i olated from rats treated with R-PIA. This loss of response was accompanied with a significant decrease in both, total 
number of adenosine A l receptors and steady-state level of o~-G i in synaptic plasma membranes. An increase in the steady-state level of 
a-G S in synaptic plasma membranes was also observed by R-PIA treatment. Concurrently, a significant increase of adenosine A j 
receptors was observed in microsomes and coated vesicles. These results demonstrate adenosine A~ receptor desensitization in rat brain 
by 'in vivo' treatment with R-PIA and suggest a role for coated vesicles in the internalization of G-protein coupled receptors. 
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1. Introduction 
When cells are exposed to agonist, in a wide variety of 
cases, there is a decline in the response of cells to a further 
exposure to the agonist. This process is called homologous 
desensitization. Based upon the studies of /3 adrenergic 
receptors, the desensitization process involves different 
and sequential steps [1]. First, agonist-dependent phospho- 
rylation of the receptor by receptor kinases leads to uncou- 
pling of the receptor from its effector [2,3]. Second, there 
is a sequestration of the receptor from plasma membrane 
to endocytotic organelles. Finally, if the challenge with the 
agonist persist, there is a proteolytic degradation of the 
receptor through a lysosomal pathway, decreasing total 
number of receptors within the cell. This process is called 
down-regulation [4]. Alteration in the rate of synthesis of 
receptors is also involved in this process [5]. The precise 
mechanism(s) by which receptors are internalized remains 
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unclear. Although different experiments, using directed 
mutagenesis, have suggested that sequestration a d down- 
regulation are separate pathways [6,7], these might share 
the same steps. On the other hand, internalization of 
G-protein coupled receptors uch as cholecystokinin recep- 
tor has recently been described through dual pathways, 
clathrin-dependent a d clathrin-independent pa hways [8]. 
Adenosine is a physiological regulator of neurotrans- 
mission, both in central and peripheral nervous system, 
which seems to mediate inhibition of excitatory neuro- 
transmitters elease. Adenosine can act through A 1 or A 2 
subtypes of receptors which mediate inhibition and stimu- 
lation of adenylyl cyclase, respectively [9]. Although ago- 
nist-induced esensitization f adenosine A~ receptors has 
been studied in a variety of cells and tissues such as 
DDT1MF-2 [10] or adipose [11], the information available 
in central nervous system is more limited and contradic- 
tory. While Abbrachio et al. [12] have shown agonist 
desensitization f adenosine A~ receptors in vitro using rat 
brain slices, Porter et al. [13] reported lack of effect on A~ 
adenosine receptor function in rat brain after in vivo 
administration of adenosine analogs. Nevertheless, other 
studies in vivo [ 14,15] have shown an increase or up-regu- 
lation of adenosine A~ receptors induced by in vivo treat- 
ment with antagonist such as caffeine or theophylline. 
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We have previously shown that adenosine A 1 receptors 
are present in bovine and rat brain-coated vesicles [16,17]. 
In these organelles, adenosine A1 receptors are coupled in 
an inhibitory manner to the adenylyl cyclase [16]. The 
presence of G-proteins [ 18,19] and other G-protein coupled 
receptors [19] in coated "vesicles have also been demon- 
strated. Clathrin-coated wmicles are subcellular organelles 
implicated in endocytotic and exocytotic protein traffic in 
eucaryotic ells [20] and have been involved in the inter- 
nalization of receptors like, transferrin receptor, LDL recep- 
tor and their ligands [21]. Recently, the involvement of 
coated vesicles in the internalization process of seven 
transmembrane domains receptors has also been described 
in yeast [22] and human kidney fibroblast cells, trans- 
formed with /3-adrenergic receptor clones [23]. In the 
present report we have investigated the desensitization f
adenosine A 1 receptor-mediated inhibition of adenylyl cy- 
clase in rat brain by in vivo administration of the adeno- 
sine A~ receptor analog R-PIA and the possible involve- 
ment of coated vesicles in the internalization of this G-pro- 
tein coupled receptor during the desensitization process. 
2. Materials and methods 
0.1 mM DTT, 0.02% NaN 3, 0.1 mM PMFS, 7.3 mU/ml 
bacitracin, pH 6.5). The homogenate was centrifuged for 
30 min at 20 000 × g and the supernatant was centrifuged 
again for 40 min at 100000 X g. The pellet was resus- 
pended in 1.5 ml of isolation buffer, homogenized using a 
Dounce glass homogenizer, mixed with an equal volume 
of Ficoll-sucrose solution (12.5% wt/v  ficoll 400, 12.5% 
wt/v  sucrose in isolation buffer) and centrifuged for 40 
min at 42 000 X g. The supernatant was diluted five times 
with isolation buffer and centrifuged at 100000 X g for 60 
min. Pellets were resuspended in 1 ml of isolation buffer, 
homogenized using a Dounce glass homogenizer and 
loaded onto a Sephacryl S-1000 column (16 X 700 mm) 
pre-equilibrated with isolation buffer. Fractions of 2 ml 
were collected using a flow of 10 ml/h. Their absorbance 
was read at 280 nm and two peaks were obtained: peak I, 
containing large membrane fragments and smooth vesicles 
and peak II, corresponding to the coated vesicles fraction. 
In order to obtain highly purified coated vesicles, peak II 
was rechromatographed on the same column and finally 
collected by centrifugation at 100000 X g for 1 h. This 
preparation yields 2.5-3 mg of coated vesicles proteins. 
The purity of this fraction was analysed by several enzyme 
markers as described earlier [16]. 
2.1. Rat treatments 2.4. Adenylyl cyclase activity 
Male Wistar rats (175--200 g) were injected for 6 days 
subcutaneously with R-PIA (one dose of 187/xg per day) 
in DMSO:water (1:1). Control rats were injected in parallel 
with vehicle alone. 
Adenylyl cyclase was measured as previously described 
[16]. Plasma membranes were always pre-treated with 
adenosine deaminase in order to remove endogenous 
adenosine. 
2.2. Synaptic plasma membranes and microsomal fraction 
isolation 
Synaptic plasma membranes were obtained following 
the method of Jones and Matus [24] by homogenization in 
TDE (5 mM Tris-HC1, 1 mM DTT, 1 mM EGTA, 10% 
sucrose, pH 7.4) and differential centrifugation, using step 
sucrose gradient. Microsomal fraction was obtained after 
centrifugation at 9000 X g for 20 min. The supernatant 
was centrifuged at 150013,0 X g for 90 min. and the pellet 
obtained, which constitutes the microsomal fraction, was 
resuspended in TDE pH 7.4 at 1-3 mg of protein/ml 
concentration. All buffers used along subcellular fraction 
isolations contained 0.1% bacitracin and 0.1% PMFS 
(phenylmethylsulphonyl fluoride) as protease inhibitors. 
2.3. Coated vesicles 
Coated vesicles were prepared as described by Bar-Zvi 
and Branton [25] and modified by Gonz~lez-Calero et al. 
[16,17]. 25-30 g of cortex from rat brain were homoge- 
nized with two burst of 15 s at high speed in a Waring 
blender in a ratio 1:3 (wt/v) tissue/isolation buffer (10 
mM MES, 100 mM KC1, 1 mm EDTA, 0.5 mM MgC12, 
2.5. Radioligand binding assays 
[3H]CHA binding was performed as described Bruns et 
al. [26]. [3H]DPCPX binding was performed according to 
the method of Lohse et al. [27]. Membranes were always 
preincubated with adenosine deaminase (0.2 U/mg of 
protein) for 30 min at 25°C in order to remove ndogenous 
adenosine. The data from saturation experiments were 
analysed by the LIGAND program [28]. 
2.6. Protein determination 
Protein was measured by the method of Lowry et al. 
[29], using bovine serum albumin as standard. 
2.7. Immunoblot analysis 
Synaptic plasma membranes or microsomes (50 /zg of 
protein) were subjected to electrophoresis on 10% poly- 
acrylamide gels in the presence of 10% SDS and elec- 
trophoretically transferred to nitro-cellulose, blocked for 1 
h with 5% (w/v)  non-fat skimmed milk in PBS (pH 7.2) 
as described earlier [30]. Blots were probed with the 
commercial antisera RM/1 (anti a-G S) and AS/7 (anti- 
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oLGil,2) from Biotechnology Systems New England Nu- 
clear Products (Boston, MA, USA). After washing with 
0.3% Tween 20 in PBS, second goat anti-rabbit antiserum 
coupled to horseradish peroxidase was added (l:1000 in 
PBS). After washing, specific bands corresponding to a-G 
protein subunits were visualized using the ECL chemilumi- 
nescent reagent kit from Amersham and quantified by 
densitometry, using the ultrascan XL LKB Bromma. 
2.8. Chemicals 
[3H]N6-Cyclohexy adenosine, CHA and [3H]8-cyclo- 
penthyl-l,3-dipropylxantine, DPCPX were purchased from 
Moraveck Biochemicals and Dupont-NEM, respectively. 
Adenosine deaminase was purchased from Boehringer- 
Mannheim. CHA and R-PIA were from Sigma. Sephacryl 
S 1000 gel filtration and Ficoll 400 were purchased from 
Pharmacia. All other reagents were from analytical grade. 
3. Results and discussion 
First, and in order to investigate the effects of R-PIA 
treatment on adenylyl cyclase, we have measured basal, 
GTP- and GTP plus forskolin-stimulated a enylyl cyclase 
activity in synaptic plasma membranes. As shown in Table 
1, R-PIA treatment significantly increased the adenylyl 
cyclase activity under the three conditions assayed, sug- 
gesting a higher steady-state level of this effector. This can 
be interpreted as a mechanism in order to counterbalance 
the persistent inhibitory effect of the adenosine analog. In 
agreement with these data, an increase in adenylyl cyclase 
activity after R-PIA administration i vivo has also been 
reported in adipocytes [11]. 
Data corresponding to adenosine A~ receptor-mediated 
inhibition of adenylyl cyclase are shown in Fig. 1. As can 
be observed, while CHA significantly inhibits forskolin- 
stimulated adenylyl cyclase in membranes from control 
rats, R-PIA treatment in vivo almost blunted the inhibitory 
effect of the adenosine A~ analog. These results demon- 
strate that R-PIA-treatment in vivo causes desensitization 
Table 1 
Effects of R-PIA treatment on adenylyl cyclase from rat synaptic plasma 
membranes 
Control R-PIA-treated 
Basal 16+ 1 (100%) 22+3 * (100%) 
GTP 25+ 1 (151%) 30+2 * (138%) 
GTP + FORSK l 18 5:5 (726%) 156 5:19 * (710%) 
Rat synaptic plasma membranes (10-20 p~g of protein) from control and 
R-PIA-treated rats were incubated as described in Section 2 in the 
absence (basal) or in the presence of 5 /.~M GTP or 5 p,M GTP plus 10 
/xM Forskolin. Data expressed as pmol/min mg pf protein are means 5: 
S.E.M. of at least 5 separate xperiments performed in triplicate; * P < 
0.05, significantly different from control. Percentages respect o each 
basal are also indicated. 
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Fig. 1. Effects of R-PIA treatment on CHA inhibition of forskolin-stimu- 
lated adenylyl cyclase. Rat synaptic plasma membranes (10-20 /zg of 
protein) from control or R-PIA-treated rats were incubated in the pres- 
ence of 5 /zM GTP plus 10 /zM forskolin and the indicated concentra- 
tions of CHA. cAMP accumulation was measured as described in Section 
2. Data, expressed as percentage respect to forskolin-stimulated adenylyl 
cyclase are means 5: S.E.M. of at least 5 separate xperiments performed 
in triplicate. * ~ P < 0.01, * P < 0.05, significantly different from each 
forskolin-stimulated adenylyl cyclase activity. Forskolin-stimulated 
adenylyl cyclase activities were 118 5:5 and 156+ 19 pmol/min per mg 
of protein for control and R-PIA treated rats, respectively. 
of adenosine A l receptor-mediated inhibition of adenylyl 
cyclase in brain, as has been described in other tissues 
[9-11], and agree with the data of Abbrachio et al. [12], 
who described esensitization f adenosine A l receptors in 
vitro using rat brain slices. 
Prolonged exposure of cells to agonist, besides uncou- 
pling, also produces a net loss of receptors from plasma 
membrane. Therefore, we have studied the status of adeno- 
sine A l receptors by radioligand binding. Table 2 summa- 
rizes data corresponding to K d and Bma x values obtained 
in brain plasma membranes from control and R-PIA-treated 
rats. As previously described [31], two populations of 
adenosine A l receptors with high and low affinity were 
detected using the adenosine analog [3H]CHA in synaptic 
plasma membranes from brain of control rats. R-PIA treat- 
Table 2 
Effect of R-PIA treatment on Adenosine A i receptor binding parameters 
in rat synaptic plasma membranes 
K d (nM) nma x(pmol/mg) 
Kdl Kd2 Bmax I Bmax2 
Cont ro l  0.79+0.01 6.3+1.5 0.20+0.01 0.955:0.23 
R-PIA-Treated - 5.65:1.6 - 0.485:0.07 *
Saturation binding experiments were performed as described in Section 2 
using [3H]CHA as radioligand. Data are means + S.E.M. of 3-12 separate 
experiments performed in triplicate; * P < 0.05, significantly different 
from control. 
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ment, caused a significanl: decrease of both populations of 
receptors, high and low affinity, without any significant 
change in K d values. This net loss of receptors in synaptic 
plasma membranes may account, at least in part, for the 
desensitization process. On the other hand, the fact that 
high affinity state receptors were undetectable after R-PIA 
treatment indicates an uncoupling of adenosine A~ recep- 
tors from its intermediary G-protein. In this sense, as in the 
case of fl-adrenergic receptor, agonist-dependent phospho- 
rylation of A I adenosine receptors in vitro has been de- 
scribed [32]. Thus, in addition to a net loss of receptors in 
plasma membrane, uncoupling also seems to operate dur- 
ing this chronic treatment. These data agree with those 
described in other non-neuronal tissues like fat cells, in 
which R-PIA administration i vivo decreased both, R- 
PIA-mediated inhibition of forskolin-stimulated a enylyl 
cyclase and adenosine A 1 receptor number [11]. On the 
other hand, adenosine A j receptor agonist-induced desen- 
sitization of adenylyl cyclase has also been reported in 
nervous system in vitro using rat brain slices [12]. Al- 
though in this case adenosine A I binding sites were unaf- 
fected by exposure of the slices to adenosine A~ analogs, 
this could be explained by the shorter time of exposure of 
the slices to the agonist (15-60 min) as compared with the 
6 days of in vivo treatment described herein. 
Other components of the adenylyl cyclase system such 
as c~-Gs and t~-G i have also been shown to be regulated 
during desensitization processes [11,33]. Therefore, we 
have analyzed the effects of R-PIA administration i vivo 
on the steady-state levels of these a-G protein subunits in 
brain synaptic plasma membranes by immunoblot. These 
results are shown in Fig. 2, where it can be observed that 
R-PIA treatment significantly decreased the steady-state 
level of a-G i and increased the steady-state l vel of both 
the 42 and 47 kDa forms of a-G s. While the decrease in 
a-G i may well account and/or contribute to explaining the 
desensitization f the inhibitory pathway of the adenylyl 
cyclase caused by R-PIA treatment, he increase of a-G s, 
could explain the enhanced GTP-stimulated adenylyl cy- 
clase activity showed in Table 1. Similar data, showing a 
decrease in the steady-state l vel of a-G~ and an increase 
in the steady-state level of a-Gs in plasma membrane from 
adipocytes after R-PIA administration i vivo have been 
reported [ l 1 ]. 
Agonist-induced down-regulation process has been ex- 
plained by degradation of receptors through a lysosomal 
pathway. Although it remains to clarify whether short-term 
agonist-induced sequestration and long term agonist-in- 
duced down-regulation may share same common steps, it 
seems clear that receptors must internalize before its degra- 
dation and/or its recycling back to plasma membrane 
takes place. Recently, another G-protein coupled receptor, 
the cholecystokinin receptor, has been shown to be inter- 
nalized by dual pathways [8], clathrin-dependent and 
clathrin-independent pa hways. Although both pathways 
lead to the formation of early endosomes, clathrin-coated 
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Fig. 2. Immunoblot analysis of a-Gi and a-G~ in synaptic plasma membranes. Rat synaptic plasma membranes (50 tzg of protein) from control (C, empty 
bars) and R-PIA treated (PIA, shaded bars) rats were subjected to SDS/PAGE, transferred electrophoretically to nitrocellulose and probed with antisera 
AS /7  (anti-ot-G i) and RM/1  (anti-ot-Gs). Then, specific bands corresponding to ot-G i (panel A) and both forms of o~-G S(panel B) were visualized and 
quantified as described in Section 2. The data, expressed as percentage of the values obtained in membranes from control rats, are mean values + S.E.M. of 
at least 5 separate xperiments. * P < 0.05, * * P < 0.01, significantly different from control. Insets show ol-G i and ot-G~ bands corresponding to 
representative immunoblots. 
172 A. Ruiz et al. / Biochimica et Biophysica Acta 1310 (1996) 168-174 
2 
Q. 
C~ 
E 
m 
o 
E 
(9 
z 
c~ 
z 
< 
"1" 
o 
_o 
LL 
O 
w r~ 
800 
700 
600 
500 
400 
300 
200 
100 
Kd (nM) Bmal~ (fmol/mg pt~) 
Kd I Kd 2 Bntax 1 Bmax 2 
CONTROL RATS 034-"0~3(3) 3.5±17(5) 90.7*_283(3) 234.1±45(5) 
TREATEORATS 041_-0.10(6) 6.7~?..1 (5) 1272+_38(6) 569.6_-117(5) * • 
O 
O 
0-p  r r i "r v 
0 2 4 6 8 10 
[3H]CHA nM 
Fig. 3. Binding of [3H]CHA to rat brain microsomes. Microsomes from (©) control and (Q)  R-PIA-treated rats were incubated in the presence of 
increasing concentrations [3H]CHA (0.15-10 riM) as described in Section 2. Non-specific binding was defined by addition of CHA at a concentration of
104 times concentration of radioligand. These curves are representative of 6 independent experiments, performed in triplicate. Mean values -1- S.E.M. of 
K d and Bma x corresponding to these experiments are indicated in the figure. * P < 0.05, significantly different from control. 
pathway has been postulated to mediate down-regulation 
via lysosomal degradation. The other pathway, related to 
smooth vesicular compartments, could be involved in the 
recycling of receptors in its way back to plasma membrane 
[8]. In this sense, it has been postulated that sequestration 
plays an important role in the recycling of receptors to 
plasma membrane in a functional/coupled state [34]. In 
order to investigate the mechanism/s of adenosine A] 
receptor internalization during a desensitization process, 
we have also studied the presence of adenosine A] recep- 
tors in microsomes and clathrin-coated vesicles. Fig. 3 
shows the effects of R-PIA treatment during 6 days on 
adenosine A~ receptors in the microsomal fraction. A 
significant increase in total receptor number, without any 
significant change in its affinity, was detected in micro- 
somes from R-PIA-treated rats. As microsomes contains 
~Gi aGs 
39KDa 42KDa 
C 100 % C 100 
PIA 91+7 % PIA 94+7 
KDa C PIA KDa C PIA 
47KDa 
100 
114+14 
Fig. 4. Immunoblot analysis of a-Gi and ot-Gs in microsomes. Microsomes (50 /xg of protein) from control (C) and R-PIA-treated (PIA) rats were 
subjected to SDS/PAGE, transferred electrophoretically to nitrocellulose and probed with antisera AS /7  (anti-ot-G i) and RM/1 (anti-a-Gs). Then, 
specific bands corresponding to ot-G i and a-G, forms (left and right inset of the bottom, respectively) were visualized and quantified as described in 
Section 2. The data, expressed as percentage of the values obtained in membranes from control rats, are mean values __. S.E.M. of, at least 5 separate 
experiments. Insets show o~-G i and a-G s bands corresponding to representative immunoblots. 
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both, smooth vesicular compartments and clathrin-coated 
vesicles, these data could be explained as an increase in 
the steady-state l vel of these receptors in the clathrin- 
coated vesicles mediated own-regulation pathway and/or 
an increase in the pool of receptors in smooth vesicular 
compartments in its recycling towards plasma membrane. 
Since G-protein subunits have also been localized in 
internal compartments, including microsomal fraction [35], 
we have studied the possibility that c~-G i were internalized 
together with adenosine A~ receptors. Thus, we have 
analyzed the possible effects of R-PIA treatment on the 
steady-state l vels of these proteins in the microsomal 
fraction by immunoblot. As shown in Fig. 4, a-G s and 
ot-G i were present in this subcellular fraction. This can 
explain the presence of high affinity state receptors in this 
subcellular fraction. Nevertheless, no significant changes 
in the steady-state level of these proteins were detected by 
R-PIA treatment, suggesting that adenosine A~ receptors 
and ~-Gi may share same internal compartments but do 
not follow the same fate or kinetics in the internalization 
and/or down-regulation processes. 
Clathrin-coated vesicles are implicated in intracellular 
membrane traffic, including endocytosis and exocytosis. 
Part of this traffic is involved in agonist-mediated endocy- 
tosis of receptors uch as transferrin receptor or LDL 
receptor and its ligands [2:1]. Another line of evidence as 
the presence of G-protein coupled receptors [16,17], in- 
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Fig. 5. Binding of [3H]DPCPX to rat brain coated vesicles. Coated 
vesicles from (O)  control and (0 )  R-PIA-treated rats were incubated at 
25°C for 2 hr in the presence of increasing concentrations of the 
adenosine A 1 antagonist [3H]DPCPX as described in Section 2. Specific 
binding was the difference between total and non-specific binding ob- 
tained in the absence or in the presence of 100 /xM R-PIA respectively. 
These curves are representative of 4 (control) or 5 (R-PIA-treated) 
independent experiments performed in triplicate. Mean values + S.E.M. of 
K d and Bma x corresponding to these experiments are included in the 
figure. Saturation curves were fitted by computer modelling (LIGAND) 
according to one-state fit. * P < 0.05, significantly different from control. 
cluding dopamine D 1 and D 2 receptors [19], G-proteins 
[18,19] and effectors [16-19] in coated vesicles, suggests 
that these organelles may participate in agonist-induced 
translocation of receptors in the sequestration and/or 
down-regulation processes. In this sense, it has been re- 
ported that clathrin facilitates internalization of 7 trans- 
membrane domains receptors in yeast [22] and recently, 
Von Zastrom and Kobilka [23] have shown that isoprote- 
renol causes fl-adrenergic receptors to cluster in coated 
invaginations. Thus, in order to investigate a possible role 
for coated vesicles during a desensitization process, the 
presence of adenosine A 1 receptors has also been analyzed 
in this subcellular fraction isolated from brain of control 
and R-PIA-treated rats. Due to the high content of non- 
membrane proteins in these vesicles, the antagonist 
[ 3 H]DPCPX, that shows a higher affinity for adenosine A~ 
receptors than CHA [27], was used in these experiments. 
The results in Fig. 5 show that R-PIA treatment also brings 
about a significant increase in the steady-state l vel of 
adenosine A~ receptors in coated vesicles. Thus, besides 
agonist-induced desensitization f adenosine A] receptors 
in rat brain by R-PIA treatment in vivo, we also present 
evidence for a clear relationship between the increase in 
adenosine A~ receptors in coated vesicles and the decline 
of these receptors in plasma membrane during a desensiti- 
zation process. These data agree with our previous reports 
describing the presence of adenosine A 1 receptors in bovine 
and rat brain coated vesicles [16,17] and with the idea that 
these subcellular organelles are involved in down-regu- 
lation of 7 trans-membrane domains receptors. Neverthe- 
less, more work has to be done to clarify how G-protein 
coupled receptors are internalized and its possible relation- 
ship with early steps of the sequestration process. 
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